Investors OurProducts Professional Patient

A world leader in mitochondrial medicine

NeuroVive develops novel mitochondria-protecting pharmaceuticals for the treatment of reperfusion injury during myocardial infarction, traumatic brain injuries (TBIs), and other acute indications where prevention of secondary tissue damage is important

» View our Corporate Fact Sheet PDF

Two potential breakthrough products in the clinic

CicloMulsion® and NeuroSTAT® are novel formulations of cyclosporine in Phase III and Phase II development respectively

» Our Products

Significant science supports the use of cyclosporine's action in acute traumatic injury

Cyclosporine protects cellular energy production by inhibiting cyclophilin-D in the membrane of the mitochondria

» Research Overview

The discovery of NeuroVive drug profiled in US pharmaceutical magazine



» In the News

Financial calendar

Subscribe
2013 Aug 23

2013 Nov 22

2014 Feb 21

About Neurovive

NeuroVive Pharmaceutical AB is a world leader in developing cyclosporine-based mitochondrial-protecting pharmaceuticals for the treatment of traumatic brain injuries (TBIs), reperfusion injury in myocardial infarction, stroke, and other acute injuries. Our advanced research program focuses on developing additional variants of cyclophilin-D-inhibiting cyclosporines and studying new ways of transporting these drugs across the blood–brain barrier to the central nervous system. Our NeuroSTAT® pharmaceutical is currently entering into a Phase II/III adaptive clinical study for TBI, while our CicloMulsion® pharmaceutical for reperfusion injury is in a 1,000-patient, Phase III, investigator-initiated clinical study.

Learn more